NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I expect that this also means that the National Institute for Health and Care Excellent (NICE) will be restarting its appraisal of the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma multiforme soon.

The appraisal was suspended because the DCVax-L Phase 3 trial results were not available because NWBio decided to wait for the long / fat tail results. I expect that once TLD is released, NWBio will provide NICE with its evidence submission, and the Project Documents will be updated.

https://www.nice.org.uk/guidance/indevelopment/gid-ta10143

If DCVax®-L is approved by NICE and then receives full regulatory approval, the NHS legally has to make the treatment available within three months.